Hall Capital Management’s iShares Biotechnology ETF IBB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,675
Closed -$218K 93
2022
Q1
$218K Sell
1,675
-688
-29% -$89.6K 0.13% 93
2021
Q4
$361K Buy
2,363
+35
+2% +$5.42K 0.2% 80
2021
Q3
$376K Buy
2,328
+390
+20% +$65.6K 0.24% 78
2021
Q2
$317K Buy
+1,938
New +$299K 0.2% 83
2020
Q4
$283K Buy
1,868
+10
+0.5% +$1.43K 0.2% 78
2020
Q3
$252K Buy
+1,858
New +$252K 0.2% 76

Other funds holding IBB

Hall Capital Management's IBB Position: Q2 2022 in Review

Hall Capital Management sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 1,675 shares — an estimated $218K sold.

Hall Capital Management first reported a position in IBB in Q3 2020 and held it in 6 quarters. The position peaked at $376K in Q3 2021. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

  • Hall Capital Management reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
  • Hall Capital Management sold 1,675 iShares Biotechnology ETF shares in Q2 2022, an estimated $218K.
  • Hall Capital Management first reported a position in iShares Biotechnology ETF in Q3 2020 and held it in 6 quarters.
  • Hall Capital Management's iShares Biotechnology ETF position peaked at $376K in Q3 2021.
  • 858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Hall Capital Management's 13F filing for Q2 2022, filed 19 Jul 2022.